SCHEMBL3366682

SCHEMBL3366682

CCOc1ccc(S(=O)(=O)N(CC(=O)NC(Cc2c[nH]c3ccccc23)C(N)=O)c2ccc(OC)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
GAA P10253 1/20 0.54
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA9 Q16790 1/20 0.54
POLB P06746 2/20 0.52
TP53 P04637 2/20 0.52
MMP9 P14780 4/20 0.51
MMP2 P08253 3/20 0.51
HCRTR1 O43613 1/20 0.51
HCRTR2 O43614 1/20 0.51
KCNA5 P22460 3/20 0.49
MAPT P10636 2/20 0.48
LMNA P02545 1/20 0.48
THRB P10828 1/20 0.48
P2RY14 Q15391 1/20 0.47
OXTR P30559 1/20 0.46
AVPR1A P37288 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3365542 0.93 CA12 (0.53) KEAP1MEN1KMT2AGAACA12
SCHEMBL6847730 0.89 CA12 (0.49) KEAP1MEN1KMT2AGAACA12
SCHEMBL3364635 0.81 MEN1 (0.58) KEAP1MEN1KMT2AGAAPOLB
SCHEMBL24024001 0.73 ECE1 (0.65) MEN1KMT2ACA12CA1CA9
SCHEMBL3365718 0.72 KMT2A (0.66) MEN1KMT2AGAAPOLBTP53
SCHEMBL31238592 0.71 ECE1 (0.64) MEN1KMT2ACA12CA1CA9
SCHEMBL3369175 0.71 MEN1 (0.56) MEN1KMT2AGAAPOLBTP53
SCHEMBL3366525 0.71 OXTR (0.73) MEN1KMT2AGAAPOLBTP53
SCHEMBL3366530 0.71 OXTR (0.73) MEN1KMT2AGAAPOLBTP53
SCHEMBL7382309 0.70 KCNA5 (0.83) MMP9MMP2KCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1335901-B1 PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES MERCK SERONO SA (CH) 2010-04-14 EP claimed
US-7312358-B2 Pharmaceutically active sulfanilide derivatives LABORATOIRES SERONO SA (CH) 2007-12-25 US claimed
US-20040072816-A1 Pharmaceutically active sulfanilide derivatives MERCK SERONO SA (CH) 2004-04-15 US claimed
EP-1335901-A1 PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2003-08-20 EP claimed
WO-2002032864-A1 PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2002-04-25 WO claimed
EP-1335901-B1 PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES MERCK SERONO SA (CH) 2010-04-14 EP disclosed
US-7312358-B2 Pharmaceutically active sulfanilide derivatives LABORATOIRES SERONO SA (CH) 2007-12-25 US disclosed
US-7312358-B2 Pharmaceutically active sulfanilide derivatives LABORATOIRES SERONO SA (CH) 2007-12-25 US disclosed
US-7312358-B2 Pharmaceutically active sulfanilide derivatives LABORATOIRES SERONO SA (CH) 2007-12-25 US disclosed
US-20040072816-A1 Pharmaceutically active sulfanilide derivatives MERCK SERONO SA (CH) 2004-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072816-A1 Pharmaceutically active sulfanilide derivatives OXTR, AVPR2, OPRL1 KEAP1 2923/4885MEN1 4427/4885KMT2A 4349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.